Form D · Biotechnology
AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC.
Rockville, MD · CIK 0001586824
Offering snapshot reported Dec 22, 2025 · SEC filing
- Reported sold
- $310K Offering amount: $10M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 3, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
- Reported investors0 → 4
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 22, 2025 | Amendment | $310,000 | No comparison | 4 | SEC filing |
| Nov 18, 2025 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Nov 12, 2015 | Initial | $1,163,007 | No comparison | 14 | SEC filing |
| Oct 3, 2014 | Initial | $340,992 | No comparison | 1 | SEC filing |
| Sep 16, 2013 | Initial | $1,324,999 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-564282
SAFE (Simple Agreement for Future Equity)
Source: Form D, filed Dec 22, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey Adam Galvin | Director, Executive |
| William Drew Palin | Director, Executive |
| Barry Haden Wells | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
108 Monroe Street, Suite 202
Rockville, MD, 20850
Rockville, MD, 20850